Home / Stocks / ASND

Ascendis Pharma A/S (ASND, Biotech) Stock Valuation & Fair Value

No P/E valuation

Ascendis Pharma A/S (ASND, Biotech) trades at a current P/E of 19.4, trading without a historical P/E to compare against, with a forward growth estimate of 10.3% and a PEG of 1.89. Analysts' one-year estimates have been hit 30% of the time.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-11-07
Current P/E
19.4
Normal P/E
—
PEG
1.89
Fwd growth
10.3%
Div yield
0.0%
RSI (14)
64.9
Neutral
Technical context
  • Price $256.82 at the Nov 6 close, 6.3% above the 20-day average ($241.54) and 5.9% above the 50-day ($242.50).
  • RSI (14) at 64.9.
  • 52-week range $196.01 to $277.18: the price is 7.3% below the high and 31.0% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ASND is $304.19 across 22 analysts, 18.4% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: we publish none, because it has no P/E to compare against its own history. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

Current P/E and rating by weekCurrent P/E moved from 33.7 to 19.0 between 2026-07-31 and 2026-10-30, with 0 rating changes over 14 recorded weeks.2026-07-31: P/E 33.7, No P/E valuation, recalculated for the week of 2026-07-312026-07-31: P/E 32.5, No P/E valuation, recorded live 2026-08-032026-08-07: P/E 32.5, No P/E valuation, recalculated for the week of 2026-08-072026-08-07: P/E 32.3, No P/E valuation, recorded live 2026-08-102026-08-14: P/E 32.3, No P/E valuation, recalculated for the week of 2026-08-142026-08-14: P/E 33.7, No P/E valuation, recorded live 2026-08-172026-08-21: P/E 33.7, No P/E valuation, recalculated for the week of 2026-08-212026-08-21: P/E 27.6, No P/E valuation, recorded live 2026-08-242026-08-27: P/E 27.6, No P/E valuation, recalculated for the week of 2026-08-272026-08-28: P/E 27.6, No P/E valuation, recalculated for the week of 2026-08-282026-08-28: P/E 27.6, No P/E valuation, recalculated for the week of 2026-08-302026-08-28: P/E 25.9, No P/E valuation, recorded live 2026-08-312026-09-04: P/E 25.9, No P/E valuation, recalculated for the week of 2026-09-052026-09-04: P/E 27.1, No P/E valuation, recorded live 2026-09-072026-09-11: P/E 27.1, No P/E valuation, recalculated for the week of 2026-09-122026-09-11: P/E 25.4, No P/E valuation, recorded live 2026-09-142026-09-18: P/E 25.4, No P/E valuation, recalculated for the week of 2026-09-192026-09-18: P/E 22.1, No P/E valuation, recorded live 2026-09-212026-09-25: P/E 22.1, No P/E valuation, recalculated for the week of 2026-09-262026-09-25: P/E 20.3, No P/E valuation, recorded live 2026-09-282026-10-02: P/E 20.3, No P/E valuation, recalculated for the week of 2026-10-032026-10-02: P/E 19.9, No P/E valuation, recorded live 2026-10-052026-10-09: P/E 19.9, No P/E valuation, recalculated for the week of 2026-10-102026-10-09: P/E 19.4, No P/E valuation, recorded live 2026-10-122026-10-16: P/E 19.4, No P/E valuation, recalculated for the week of 2026-10-172026-10-16: P/E 18.2, No P/E valuation, recorded live 2026-10-192026-10-23: P/E 18.9, No P/E valuation, recorded live 2026-10-262026-10-30: P/E 18.9, No P/E valuation, recalculated for the week of 2026-10-312026-10-30: P/E 19.0, No P/E valuation, recorded live 2026-11-0220.025.030.0Jul 31Aug 23Sep 15Oct 7Oct 30
No P/E valuationNo P/E valuationNo P/E valuationLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 33.7not availableNo P/E valuation (recalculated)
2026-10-19P/E 18.2not availableNo P/E valuation
2026-11-02P/E 19.0not availableNo P/E valuation ← now
Show all 29 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 33.7not availableNo P/E valuation (recalculated)
2026-08-03P/E 32.5not availableNo P/E valuation
2026-08-07P/E 32.5not availableNo P/E valuation (recalculated)
2026-08-10P/E 32.3not availableNo P/E valuation
2026-08-14P/E 32.3not availableNo P/E valuation (recalculated)
2026-08-17P/E 33.7not availableNo P/E valuation
2026-08-21P/E 33.7not availableNo P/E valuation (recalculated)
2026-08-24P/E 27.6not availableNo P/E valuation
2026-08-27P/E 27.6not availableNo P/E valuation (recalculated)
2026-08-28P/E 27.6not availableNo P/E valuation (recalculated)
2026-08-30P/E 27.6not availableNo P/E valuation (recalculated)
2026-08-31P/E 25.9not availableNo P/E valuation
2026-09-05P/E 25.9not availableNo P/E valuation (recalculated)
2026-09-07P/E 27.1not availableNo P/E valuation
2026-09-12P/E 27.1not availableNo P/E valuation (recalculated)
2026-09-14P/E 25.4not availableNo P/E valuation
2026-09-19P/E 25.4not availableNo P/E valuation (recalculated)
2026-09-21P/E 22.1not availableNo P/E valuation
2026-09-26P/E 22.1not availableNo P/E valuation (recalculated)
2026-09-28P/E 20.3not availableNo P/E valuation
2026-10-03P/E 20.3not availableNo P/E valuation (recalculated)
2026-10-05P/E 19.9not availableNo P/E valuation
2026-10-10P/E 19.9not availableNo P/E valuation (recalculated)
2026-10-12P/E 19.4not availableNo P/E valuation
2026-10-17P/E 19.4not availableNo P/E valuation (recalculated)
2026-10-19P/E 18.2not availableNo P/E valuation
2026-10-26P/E 18.9not availableNo P/E valuation
2026-10-31P/E 18.9not availableNo P/E valuation (recalculated)
2026-11-02P/E 19.0not availableNo P/E valuation ← now

Frequently asked questions

Is Ascendis Pharma A/S stock overvalued?

At a current P/E of 19.4, Ascendis Pharma A/S has no historical normal P/E on record to compare that against, with a PEG of 1.89 on 10.3% forward growth. tickerseer therefore publishes no valuation rating for it.

What is Ascendis Pharma A/S's fair value and PEG?

Ascendis Pharma A/S trades at a current P/E of 19.4, a PEG of 1.89, and a forward growth estimate of 10.3%.

Has tickerseer's rating of Ascendis Pharma A/S changed?

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

What is the analyst price target for Ascendis Pharma A/S?

The mean Wall Street price target for Ascendis Pharma A/S is $304.19 across 22 analysts, 18.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ASND free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.